SAREUM HOLDINGS PLC Logo

SAREUM HOLDINGS PLC

Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.

SAR | IL

Overview

Corporate Details

ISIN(s):
GB00BMC3RJ87
LEI:
213800PKERN2DY8FFM72
Country:
United Kingdom
Address:
UNIT 2A, CB22 3FX CAMBRIDGE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Sareum Holdings PLC is a clinical-stage drug discovery and development company specializing in small molecule therapeutics. The company develops next-generation kinase inhibitors to treat autoimmune diseases and cancer. Its primary focus is on the TYK/JAK kinase cell signalling family, advancing dual inhibitors of TYK2 and JAK1, which it believes offer superior efficacy compared to single-kinase agents. The company's lead autoimmune candidate, SDC-1801, has successfully completed a Phase 1 clinical trial. Sareum's pipeline also includes a Chk1 kinase inhibitor program for oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 08:00
Legal Proceedings Report
Update on toxicology study for SDC-1801
English 13.2 KB
2025-10-07 08:00
Report Publication Announcement
Notice of Results and Investor Presentation
English 12.2 KB
2025-09-26 16:12
Share Issue/Capital Change
Exercise of Warrants
English 10.8 KB
2025-09-18 13:59
Share Issue/Capital Change
Exercise of Warrants
English 10.9 KB
2025-08-26 08:00
Share Issue/Capital Change
Exercise of Warrants
English 10.5 KB
2025-08-20 11:01
Share Issue/Capital Change
Exercise of Warrants
English 10.5 KB
2025-08-12 08:00
Regulatory News Service
Sareum Collaboration with Receptor.AI
English 15.3 KB
2025-07-09 08:00
Share Issue/Capital Change
Exercise of Warrants
English 10.7 KB
2025-05-29 08:00
Regulatory News Service
Initiation of Toxicology Studies for SDC-1801
English 11.4 KB
2025-03-27 08:00
Director's Dealing
Director’s Dealing
English 27.8 KB
2025-03-25 08:00
Interim Report
Sareum Half-Year Report
English 133.9 KB
2025-03-13 08:15
Share Issue/Capital Change
Institutional Equity Fundraise
English 14.4 KB
2025-03-13 08:08
Regulatory News Service
Sareum Acquires Licence for SRA737
English 12.8 KB
2024-12-31 08:00
Legal Proceedings Report
Update on SRA737
English 13.5 KB
2024-12-19 17:07
Post-Annual General Meeting Information
Results of AGM
English 33.8 KB

Automate Your Workflow. Get a real-time feed of all SAREUM HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SAREUM HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom OBD
Pharnext Logo France ALPHA
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.